Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease

References

• Libby P., Ridker P. M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95
   PubMed Web of Science ®Google Scholar
• Apple F. S., Wu A. H., Mair J., Ravkilde J., Panteghini M., Tate J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810–24
   PubMed Web of Science ®Google Scholar
• de Nooijer R., Verkleij C. J., von der Thusen J. H., Jukema J. W., van der Wall E. E., van Berkel T. J., et al. Lesional overexpression of matrix metalloproteinase‐9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 340–6
   PubMed Web of Science ®Google Scholar
• Kranzhofer A., Baker A. H., George S. J., Newby A. C. Expression of tissue inhibitor of metalloproteinase‐1, ‐2, and ‐3 during neointima formation in organ cultures of human saphenous vein. Arterioscler Thromb Vasc Biol 1999; 19: 255–65
   PubMed Web of Science ®Google Scholar
• Yasmin, McEniery C. M., Wallace S., Dakham Z., Pulsalkar P., Maki‐Petaja K., et al. Matrix metalloproteinase‐9 (MMP‐9), MMP‐2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 372, 25
   PubMed Web of Science ®Google Scholar
• Bayes‐Genis A., Conover C. A., Overgaard M. T., Bailey K. R., Christiansen M., Holmes D. R., et al. Pregnancy‐associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022–9
   PubMed Web of Science ®Google Scholar
• Conti E., Andreotti F., Zuppi C. Pregnancy‐associated plasma protein A as predictor of outcome in patients with suspected acute coronary syndromes. Circulation 2004; 109: e211–12
   PubMed Web of Science ®Google Scholar
• Cosin‐Sales J., Kaski J. C., Christiansen M., Kaminski P., Oxvig C., Overgaard M. T., et al. Relationship among pregnancy associated plasma protein‐A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 2093–8
   PubMed Web of Science ®Google Scholar
• Lehoux S., Tedgui A. Making up and breaking up: the tortuous ways of the vascular wall. Arterioscler Thromb Vasc Biol 2005; 25: 892–4
   PubMed Web of Science ®Google Scholar
• Whatling C., McPheat W., Hurt‐Camejo E. Matrix management: assigning different roles for MMP‐2 and MMP‐9 in vascular remodeling. Arterioscler Thromb Vasc Biol 2004; 24: 10–11
   PubMed Web of Science ®Google Scholar
• Burr M. L., Fehily A. M., Gilbert J. F., Rogers S., Holliday R. M., Sweetnam P. M., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2((8666))757–61
   PubMed Web of Science ®Google Scholar
• de Logeril M., Renaud S., Mamelle N., Salen P., Martin J. L., Monjaud I., et al. Mediterranean alpha‐linolenic acid‐rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343((8911))1454–9
   PubMed Web of Science ®Google Scholar
• Marckmann P., Gronbaek M. Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. Eur J Clin Nutr 1999; 53: 585–90
   PubMed Web of Science ®Google Scholar
• Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354((9177))447–55
   PubMed Web of Science ®Google Scholar
• Eritsland J., Arnesen H., Gronseth K., Fjeld N. B., Abdelnoor M. Effect of dietary supplementation with n‐3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31–6
   PubMed Web of Science ®Google Scholar
• Mori T. A., Beilin L. J. Omega‐3 fatty acids and inflammation. Curr Atheroscler Rep 2004; 6: 461–7
   PubMedGoogle Scholar
• Johansen O., Brekke M., Seljeflot I., Abdelnoor M., Arnesen H. N‐3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol 1999; 33: 1619–26
   PubMed Web of Science ®Google Scholar
• Hjerkinn E. M., Seljeflot I., Ellingsen I., Berstad P., Hjermann I., Sandvik L., et al. Influence of long‐term intervention with dietary counseling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. Am J Clin Nutr 2005; 81: 583–9
   PubMed Web of Science ®Google Scholar
• Hjermann I., Velve B. K., Holme I., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981; 2((8259))1303–10
   PubMed Web of Science ®Google Scholar
• Folch J., Lees M., Sloane Stanley G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497–509
   PubMed Web of Science ®Google Scholar
• Hoshi M., Williams M., Kishimoto Y. Esterification of fatty acids at room temperature by chloroform‐methanolic HCl‐cupric acetate. J Lipid Res 1973; 14: 599–601
   PubMed Web of Science ®Google Scholar
• Persson J., Stavenow L., Wikstrand J., Israelsson B., Formgren J., Berglund G. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992; 12: 261–6
   PubMed Web of Science ®Google Scholar
• Hjerkinn E. M., Abdelnoor M., Breivik L., Bergengen L., Ellingsen I., Seljeflot I., et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2006; 13: 325–33
   PubMedGoogle Scholar
• Ercan E., Tengiz I., Altuglu I., Sekuri C., Aliyev E., Ercan H. E., et al. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol Pol 2004; 60: 454–8
   PubMedGoogle Scholar
• Roberts C. K., Won D., Pruthi S., Kurtovic S., Sindhu R. K., Vaziri N. D., et al. Effect of a short‐term diet and exercise intervention on oxidative stress, inflammation, MMP‐9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657–65
   PubMed Web of Science ®Google Scholar
• Aarsetoy H., Brugger‐Andersen T., Hetland O., Grundt H., Nilsen D. W. Long‐term influence of regular intake of high dose n‐3 fatty acids on CD40‐ligand, pregnancy‐associated plasma protein A and matrix metalloproteinase‐9 following acute myocardial infarction. Thromb Haemost 2006; 95: 329–36
   PubMed Web of Science ®Google Scholar
• Harris M. A., Hansen R. A., Vidsudhiphan P., Koslo J. L., Thomas J. B., Watkins B. A., et al. Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 23–9
   PubMed Web of Science ®Google Scholar
• Li H., Simon H., Bocan T. M., Peterson J. T. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE‐ and MMP‐inhibition. Cardiovasc Res 2000; 46: 298–306
   PubMed Web of Science ®Google Scholar
• Luan Z., Chase A. J., Newby A. C. Statins inhibit secretion of metalloproteinases‐1, ‐2, ‐3, and ‐9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769–75
   PubMed Web of Science ®Google Scholar
• Nakamura T., Matsuda T., Suzuki Y., Ueda Y., Koide H. Effects of low‐density lipoprotein apheresis on plasma matrix metalloproteinase‐9 and serum tissue inhibitor of metalloproteinase‐1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J 2003; 49: 430–4
   PubMed Web of Science ®Google Scholar
• Seagrave J., Barr E. B., March T. H., Nikula K. J. Effects of cigarette smoke exposure and cessation on inflammatory cells and matrix metalloproteinase activity in mice. Exp Lung Res 2004; 30: 1–15
   PubMed Web of Science ®Google Scholar
• Nordskog B. K., Blixt A. D., Morgan W. T., Fields W. R., Hellmann G. M. Matrix‐degrading and pro‐inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate. Cardiovasc Toxicol 2003; 3: 101–17
   PubMedGoogle Scholar
• Derosa G., D'Angelo A., Ciccarelli L., Piccinni M. N., Pricolo F., Salvadeo S., et al. Matrix metalloproteinase‐2, ‐9, and tissue inhibitor of metalloproteinase‐1 in patients with hypertension. Endothelium 2006; 13: 227–31
   PubMed Web of Science ®Google Scholar
• Tayebjee M. H., Nadar S., Blann A. D., Gareth B. D., MacFadyen R. J., Lip G. Y. Matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764–9
   PubMed Web of Science ®Google Scholar
• Lee S. W., Song K. E., Shin D. S., Ahn S. M., Ha E. S., Kim D. J., et al. Alterations in peripheral blood levels of TIMP‐1, MMP‐2, and MMP‐9 in patients with type‐2 diabetes. Diabetes Res Clin Pract 2005; 69: 175–9
   PubMed Web of Science ®Google Scholar
• Jacqueminet S., Ben A. O., Chapman M. J., Nicolay N., Foglietti M. J., Grimaldi A., et al. Elevated circulating levels of matrix metalloproteinase‐9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006; 367: 103–7
   PubMed Web of Science ®Google Scholar
• Death A. K., Fisher E. J., McGrath K. C., Yue D. K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263–9
   PubMed Web of Science ®Google Scholar